Navigation Links
Signum Biosciences Awarded Two Additional NIH Grants for Development of Topical Therapeutics

PRINCETON, N.J., Sept. 20 /PRNewswire/ -- Signum Biosciences, Inc. was recently awarded two Small Business Innovation Research (SBIR) Phase I grants by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a division of the NIH, totaling over $684,000 for development of novel G-protein coupled receptor (GPCR) modulating therapeutics designed to treat common skin disorders.  

Through the first SBIR grant, Signum will develop anti-inflammatory agents to reduce chronic redness (erythema) associated with eczema, atopic dermatitis, and rosacea. Access to more effective therapies is of significant importance to a large patient population suffering from chronic skin disease. Signum's Signal Transduction Modulator (STM) technology has already demonstrated significant reduction of redness in a double-blinded placebo controlled clinical study.

A second SBIR grant was awarded to fund Signum's identification and development of multi-functional, safe, topical anti-acne therapeutics. Acne is the most common disorder of the human skin and affects up to 80% of individuals at some point in their lives. Signum's STM technology has shown potential to reduce both inflammation and infection associated with acne.  

"We are proud to be awarded additional grants by the NIH, further supporting our unique approach and scientific direction. Our objective continues to be development of our technology with the goal of improving quality of life for the large number of patients suffering from skin disease," stated Dr. Braham Shroot, Chief Executive Officer of Signum.  Signum has a history of successful grant funding including four NIH SBIRs for skin therapeutics totaling over $2.5M.  The company is currently in the second year of a two year $1.6 M phase II SBIR grant for the development of a rosacea therapeutic which will enter the clinic next year.  

About Signum Biosciences.

Signum Biosciences is a private biotechnology company dedicated to developing small-molecule therapeutics derived from its Signal Transduction Modulation (STM) platform to modulate signal transduction imbalances. Through research on protein networks that control biological systems, Signum is developing GPCR based therapeutic candidates for skin diseases.  Signum's STM technology provides many opportunities for the development of pharmaceutical candidates in age-related pathologies.

For more information on Signum and the STM technology, please, visit:

SOURCE Signum Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
2. Signum Biosciences, Inc. Announces Commercial Launch of Arazine™
3. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
7. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
8. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
9. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
10. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
11. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
Post Your Comments:
(Date:11/24/2015)... and BERN, Switzerland , November ... ARTORG Center for Biomedical Engineering Research of the University ... Division of Endocrinology, Diabetes and Clinical Nutrition of the ... start of an exclusive collaboration to develop a novel ... for the personalised delivery of insulin for diabetic patients ...
(Date:11/24/2015)... FLINT, Mich. , Nov. 24, 2015 Diplomat ... , Senior Vice President of Clinical Services, Education and Human ... (AIS) online webinar, "Oral Oncology Drugs: Health Plan Strategies for ... co-presenting with Beckie Fenrick , a consultant with the ... The webinar will ...
(Date:11/24/2015)... 24, 2015 iRhythm Technologies, Inc. , a leading ... announced that it will participate in the 27th Annual Piper Jaffray ... New York, NY . Kevin King , Chief ... 1, 2015 at 8:50am ET. --> ... . --> . --> iRhythm is ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... ... “While riding the bus, I saw a passenger in a wheelchair drenched ... be a convenient and comfortable way to protect them from bad weather, so I ... travel during cold or inclement weather. In doing so, it ensures that the user ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract Development ... expansion of its current state of the art research, development and manufacturing facility ... increase its manufacturing capacity as well as to support its clients’ growing research ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to be thankful ... Create Real Impact awards. California Casualty is proud to support the contest ... distracted and reckless driving, the number one killer of young drivers. , Almost ...
(Date:11/24/2015)... Mississauga, ON (PRWEB) , ... November 24, 2015 , ... ... Deborah Williams without a referral for dental implants at her Mississauga, ON ... qualified and experienced in the placement of dental implants. , Missing teeth can ...
(Date:11/24/2015)... ... November 25, 2015 , ... Catalent ... for drugs, biologics, consumer health and global clinical supply services, today announced that ... Clinical Trial Supply East Asia Conference, to be held at the InterContinental Seoul ...
Breaking Medicine News(10 mins):